30 closest matches · ranked by relevance
Breast Cancer · Breast Neoplasms
Primary: Number of Participants Who Were Successfully Accrued in the Study, as a Measure of Feasibility — 35 participants
Non-small Cell Lung Cancer
Primary: Local Failure Free Survival — 9.4; 9.9 months
Metastatic Triple Negative Breast Cancer
Primary: Asses the Maximum Tolerated Dose (MTD) of L-NMMA When Combined With Docetaxel/Amlodipine in the Treatment of Refractory Locally Advanced or Metastatic TNBC Patients…
Breast Cancer
Primary: Test the Clinical Effectiveness of Concurrent Paclitaxel and Radiation in a Multiethnic Cohort
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Carcinoma, Non Small Cell Lung (NSCLC)
Primary: The Metabolic Complete Response Rate, Assessed Using Interim PET-CT, in an Accelerated Fashion (2 Gy/Fraction, 6 Fractions/Week) With Concurrent Chemotherapy — 1; 6; 1…
Malignant Non-small Cell Neoplasm of Lung Stage Ia
Primary: Local Tumor Control Rate 1 Year After Percutaneous Radiofrequency Ablation (RFA) — 5 Participants
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Major Pathologic Response (MPR) — 20.3 percentage of participants — p=<.0001
Melanoma
Primary: Th1/Th2 Normalized Gene Expression — 1.029; 0.119; 0.074; 0.192 fold change
STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER
Primary: 2-year Overall Survival (Phase II) — 66.5; 55.5 percentage of participants
HPV-Related Squamous Cell Carcinoma · HNSCC
Primary: Evaluate the Tumor Shrinkage (%) to Measure the Deep Response Rate (DRR) — 25; 26; 0 Participants
Non-small Cell Lung Cancer, NSCLC
Primary: Progression-Free Survival (PFS) — 19 Participants
Locally Advanced Pancreatic Adenocarcinoma
Primary: Number of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 4; 23 Participants
Head and Neck Cancer
Primary: Clinical Response Rate Following Induction Chemotherapy — 10; 20; 9 Participants
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042
Non-small Cell Lung Carcinoma
Primary: Surgical Feasibility Rate as Measured by the Number of Subjects Who Undergo Surgery Following Neoadjuvant Pembrozulimab — 24 Participants
Stage T3-4NxM0 Gastric Cancer
Primary: Number of Participants With Pathological Response — 0; 4; 8; 3 Participants
Pancreatic Neoplasms
Primary: Kaplan-Meier Estimates for Time to Treatment Failure (TTF) — 9.0 months
Carcinoma, Non-Small-Cell Lung
Primary: The Primary Goal of This Study is to Show That the Addition of Bevacizumab to Cisplatin-based Chemotherapy in the Neoadjuvant Setting for Non-squamous Cell Carcinomas…
Stage I Breast Cancer AJCC v7 · Stage IA Breast Cancer AJCC v7 · Stage IB Breast Cancer AJCC v7
Primary: Number of Participants With Residual Disease — 24 Participants
Lung Neoplasms · Carcinoma, Non-small Cell Lung
Primary: Percentage of Participants With Objective Response (OR) — 9.4 Percentage of participants
Breast Cancer · Melanoma
Primary: Concordance of Blue Dye and Lymphoseek — 1.0000 Proportion of Lymph Nodes
Non Small Cell Lung Cancer
Primary: Overall Survival — 26.81; 24.97 months — p=0.831
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
Cervical Squamous Cell Carcinoma · Adenosquamous Carcinoma · Adenocarcinoma
Primary: Overall Survival Rate
Breast Neoplasms
Primary: Objective Response (OR) — 80.0; 75.0; 36.4 Percentage of participants
Colon Cancer · Neoadjuvant Therapy
Primary: Tumor Regression Rate of MSS/pMMR Patients — 7 Participants
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) · Pancreatic Ductal Adenocarcinoma
Primary: Study Drug-related Adverse Events — 3; 6; 3; 5 Participants